Peripheral nuclear fragmentation reactions of primary Bevalac heavy ion beams are used to produce secondary beams of radioactive nuclei. The large cross section and small deflection of the projectile fragments lead to high production and delivery efficiency for these beams. Dispersive beam transport allows good separaion and purification of the desired secondary beams. ''C and 1YNe beams of high purity and good intensity (almost 0.2% of the primary beam current) are presently being used for biomedical experiments.
INTRODUCTION
It is well known1'2 that one of the primary interactions experienced by relativistic heavy ions is the peripheral nuclear collision. The main characteristic of this type of reaction is that only a small amount of excitation energy is imparted to the projectile--enough to cause a breakup of the nucleus, but insufficient to produce significant changes in the projectile's velocity or trajectory (see Fig. 1 ).
These properties of peripheral reactions can be used to produce high purity beams of specific radioactive projectile fragments with intensities adequate for many experiments.
RADIOISOTOPE PRODUCTION
The secondary beam intensity and quality are dependent in large measure on the choice of target material and thickness, as well as on the specific properties of the production reaction. Figures 2-4 reaction. Measurements by Greiner et a12 indicate that the liC is produced roughly isotropically in the projectile rest frame, and has a mean momentum value around 100 MeV/c in this rest frame. These properties were observed to be independent of beam energy and target material.
For 11C production at an average energy of 350 MeV/amu, the nuclear reaction thus contributes an angular spread of about ±10 mrad, and a momentum spread of ±1%. When multiple scattering in the target is added, the net opening half-angle is 12 mrad. The target contribution to the momentum spread is about 2% (the momentum difference between a I'C produced at the front of the target and degraded by the full target, and one produced at the target back by a degraded 1C).
BEAM SEPARATION AND TRANSPORT Figure 5 shows the beam line used for these studies. The production target is placed at Fl, the first focus of the Bevatron extracted beam. 
B) 19Ne
In another experiment, a beam of 19Ne was produced from an incident rUNe beam, the measured Bragg curve is shown in Figure 7 . The characteristics of the (20Ne, 9Ne) reaction are sufficiently similar to those for carbon that calculated transmission factors are essentially identical. Slightly lower cross sections are compensated for by slightly less divergence owing to higher initial projectile momenta. In actual fact, the obseryed intensity ratio was very close to that seen for ''C. The uses of these beams of positron emitters fall into two broad areas, nuclear medicine and radiotherapy treatment planning verification. Present and envisioned applications of radioactive beams ir nuclear medicine diagnostic procedures are numerous. For example, implantation of radioactive atoms at any specified location of the body with a bolus-determined pattern with subsequent measurement of the level of activity at the same site will provide a technique for the determination of the micro-circulation in vital organs. This could yield useful information on the physiological condition in such areas as heart-valve actions, the nervous system, etc. Implantation experiments with 11C beams have already been done using dogs. In one example, the radioactivity was deposited in the carotid artery and blood-flow mapping was done in the brain. The greatest potential value of these beams, however, will be in the localization of the Bragg peak in relation to the tumor volume to be treated. This verification is of utmost importance for effective heavy particle cancer radiotherapy. It is difficult to calculate the density of tissue through which the beam must pass before stopping because variations in the amount of bone, blood, fat, air, tissue, etc. to be penetrated. CT scans dramatically improve treatment planning, although the treatment verification precision will still be inadequate in a number of cases. 
